Attention Deficit Hyperactivity Disorder is characterized by pervasive patterns of inattention, impulsivity, and hyperactivity, symptoms that often persist into adulthood and severely impact daily functioning and quality of life. While pharmacological treatments like stimulants remain the mainstay of therapy, patient responses vary widely, with some individuals experiencing remarkable symptomatic relief and others showing disappointing or negligible improvements. Until now, predicting who would benefit from treatment—and tailoring interventions accordingly—has remained a clinical challenge, largely due to the lack of reliable biological biomarkers.

The study’s authors addressed this challenge by focusing on the gyrification index, a neuroanatomical feature reflecting the degree of cortical folding in the human brain. Cortical gyrification develops dynamically during early brain maturation, influenced by genetic, epigenetic, and environmental factors. Abnormal gyrification patterns have previously been implicated in several psychiatric conditions, including schizophrenia and autism spectrum disorder, providing a tantalizing hint that these structural parameters might also predict therapeutic responses in neurodevelopmental disorders like ADHD.

Leveraging advanced neuroimaging techniques and sophisticated computational algorithms, the researchers quantified cortical gyrification across the cerebral cortex in a cohort of adult ADHD patients prior to treatment initiation. The study population underwent rigorous clinical evaluations to characterize symptom severity and functional impairments before being administered standard ADHD pharmacotherapies. Subsequent assessments after initial treatment phases allowed for correlation analyses between baseline gyrification patterns and clinical outcomes.

What emerged from the data was a robust association: individuals exhibiting distinct gyrification patterns within specific cortical regions demonstrated significantly better initial responses to ADHD medications. Notably, regions linked to executive functioning and attentional control—such as the prefrontal cortex and anterior cingulate—showed the most pronounced gyrification differences correlating with positive treatment effects. These findings suggest that the microarchitectural landscape of the brain might underpin the efficacy of pharmacological interventions targeting neurotransmitter systems implicated in ADHD pathology.

This study’s methodological innovations deserve attention. Employing high-resolution magnetic resonance imaging (MRI), the researchers extracted precise cortical folding metrics, which were then subjected to rigorous statistical modeling to isolate predictive markers. Incorporation of machine learning algorithms enhanced predictive accuracy, highlighting the promise of combining neuroimaging with artificial intelligence to personalize psychiatric treatment strategies. Such a paradigm might transform current symptom-based approaches into predictive models grounded in objective neurobiological data.

Furthermore, the researchers ensured careful control for confounding variables such as age, sex, medication history, and comorbid psychiatric conditions, bolstering the validity of their findings. The multi-site nature of the study further strengthens generalizability, addressing one of the recurrent limitations in neuropsychiatric research. This robustness underscores cortical gyrification as a candidate biomarker ready for subsequent validation in larger, more diverse populations.

Beyond its clinical ramifications, the study opens intriguing questions about the developmental trajectories leading to varied gyrification patterns in ADHD brains. Since gyrification is highly susceptible to early-life influences, including prenatal environment and childhood adversity, future research may decode how these factors interact with genetic predispositions to shape treatment responsiveness. This perspective encourages a more integrative model encompassing neurodevelopmental biology, environmental exposures, and lifelong brain plasticity.

The translational impact of these results is significant. If gyrification indices can reliably forecast treatment responsiveness, clinicians could employ neuroimaging scans to tailor ADHD therapies from the outset, minimizing trial-and-error prescribing and reducing patient burden. This precision approach would lead to optimized therapeutic outcomes, enhance adherence, and potentially mitigate long-term negative consequences of untreated or inadequately treated ADHD symptoms.

Critically, while this study emphasizes initial treatment response, it prompts exploration into whether gyrification patterns also predict sustained therapeutic effectiveness and functional recovery over extended periods. Incorporation of longitudinal designs and multimodal imaging could refine understanding of how cortical structure relates to dynamic treatment trajectories. These insights could further refine guidelines for pharmacological and adjunctive behavioral interventions.

Attention must also be paid to the biological mechanisms linking gyrification and treatment response. Altered cortical folding might reflect underlying variations in neuronal connectivity, synaptic density, or neurochemical signaling within pivotal brain circuits targeted by ADHD medications. Experimental studies dissecting these neural substrates may illuminate novel targets for pharmacological development, with the ultimate goal of enhancing treatment efficacy beyond current standards.

Importantly, this work contributes to a growing movement challenging conventional diagnostic frameworks that rely solely on symptom clusters. By anchoring psychiatric diagnoses in neurobiological substrates, such research catalyzes the shift toward a neuroscience-informed psychiatric nosology. This reframing is essential for resolving heterogeneity in clinical presentations and forging stratified intervention pathways.

Moreover, the integration of cortical gyrification metrics into clinical workflows could be facilitated by advances in imaging technology and analytic pipelines, making such assessments increasingly accessible and cost-effective. Collaborations between neuroscientists, clinical psychiatrists, and data scientists will be pivotal in translating these findings from research settings into practical clinical tools.

In sum, this exciting study highlights the immense potential of cortical gyrification as a biomarker for predicting initial treatment response in adults with ADHD. It sets the stage for future investigations aimed at verifying these markers across populations, elucidating their biological underpinnings, and embedding them within precision psychiatry frameworks. As we continue to unravel brain-behavior relationships, such advances promise to elevate patient care by delivering more targeted, effective, and personalized interventions for complex neurodevelopmental disorders.

The path ahead calls for multidisciplinary efforts to not only replicate and expand upon these findings but also to integrate cortical morphometric data with genomic, cognitive, and environmental datasets. Harnessing this rich confluence of information could usher in a new era of individualized medicine in ADHD and beyond, transforming decades of elusive treatment challenges into opportunities for unequivocal clinical progress.

Subject of Research: Cortical gyrification as a biomarker to predict initial treatment response in adults with ADHD.

Article Title: Cortical gyrification predicts initial treatment response in adults with ADHD.

Article References:
Laatsch, J., Stein, F., Maier, S. et al. Cortical gyrification predicts initial treatment response in adults with ADHD. Transl Psychiatry 15, 406 (2025). https://doi.org/10.1038/s41398-025-03681-0

DOI: https://doi.org/10.1038/s41398-025-03681-0

ADHD has long been recognized as a neurodevelopmental disorder predominantly diagnosed in children, characterized by impulsivity, hyperactivity, and inattention. However, recent epidemiological data reveal a striking rise in adult ADHD diagnoses, a phenomenon particularly evident in Estonia, where numbers have dramatically increased in the past five years. This trend aligns with international observations, suggesting that ADHD symptoms manifest persistently into adulthood or may initially emerge later in life, warranting urgent scientific attention.

Despite extensive research on pediatric ADHD, adult presentations of the disorder remain poorly understood, especially concerning their etiological complexity. Adult ADHD is complicated by the frequent presence of comorbid mental health disorders such as depression and anxiety, and overlaps symptomatically with conditions driven by environmental stressors including chronic fatigue and psychosocial pressures. This diagnostic ambiguity contributes to underdiagnosis or misdiagnosis, impeding effective treatment and negatively impacting patient outcomes.

Professor Lehto highlights a critical gap in current psychiatric practice: the absence of objective biological markers for ADHD. Presently, diagnoses depend heavily on subjective patient reports and clinical assessments, which can be inconsistent and influenced by overlapping symptomatology. This reliance underscores the necessity for novel biologically grounded diagnostic tools that can differentiate ADHD from other mental health conditions with greater precision.

The project’s core scientific innovation resides in employing high-dimensional genetic data derived from large biobanks, which include the University of Tartu’s Estonian Biobank and similar repositories across Norway, the Netherlands, Sweden, and the United Kingdom. By analyzing genome-wide association study (GWAS) data in conjunction with detailed phenotypic information encompassing lifestyle factors such as smart device usage, the research team intends to dissect the polygenic architecture of adult ADHD symptoms.

One of the major challenges the project addresses is disentangling which clinical traits are genuinely driven by underlying genetic risk factors associated with ADHD versus those attributable to external influences or comorbidities. This distinction is vital not only for understanding pathophysiology but also for developing targeted interventions. The researchers hypothesize that specific gene variants contribute differentially to discrete symptom clusters, an insight that could transform psychiatric nosology.

Employing cutting-edge machine learning algorithms, the project will analyze extensive questionnaire data capturing hundreds of mental health symptoms, personality traits, and lifestyle variables. This computational approach allows for the identification of symptom clusters that most strongly correlate with genetic susceptibility to ADHD. Such data-driven stratification aims to create a biologically informed phenotype classification rather than relying solely on traditional symptom checklists.

The culmination of these efforts will be the design of an innovative, biology-based screening tool for adult ADHD diagnosis. Importantly, the intended questionnaire format is envisioned as a cost-effective and accessible alternative to genetic testing, democratizing early and accurate detection. This advancement has the potential to revolutionize clinical workflows by enabling clinicians to identify previously undiagnosed adults who have been coping with ADHD-related impairments throughout their lives.

Beyond ADHD, Professor Lehto emphasizes that the methodology developed may have broader applications in psychiatry, where multiple disorders exhibit overlapping symptoms and shared genetic risk factors. A more precise, genetics-informed framework for diagnosing mental health conditions could improve treatment personalization and efficacy across various psychiatric illnesses.

The research is supported by a competitive European Commission grant amounting to nearly €1.5 million, underscoring the significance and expected impact of the work. The grant selection process was highly rigorous, with only 12% of proposals funded from a large pool of over 3,900 applicants, highlighting the project’s scientific excellence and innovation.

This interdisciplinary endeavor, at the interface of neuropsychiatric genomics, psychology, and data science, exemplifies a modern approach to complex mental health disorders. It leverages vast datasets and computational power to decode the intricate web of genetics and environment contributing to adult ADHD. The anticipated outcomes promise not only diagnostic innovation but also deeper mechanistic insights that could guide future therapeutic targets.

In conclusion, Kelli Lehto’s project represents a pivotal advancement in psychiatric research, pushing the boundaries of knowledge about adult ADHD and underscoring the increasing importance of integrating genetic and environmental data. The novel diagnostic tools resulting from this research could alleviate the significant burden of undiagnosed ADHD in adults, offering hope for improved quality of life through timely and tailored interventions.

Subject of Research: Genetic and environmental determinants of adult ADHD; development of biology-based diagnostic tools for adult ADHD.

Article Title: Decoding Adult ADHD: Pioneering Genetics and Machine Learning to Revolutionize Diagnosis

News Publication Date: Information not provided.

Web References: University of Tartu Estonian Biobank

References: Information not provided.

Image Credits: Photo by Andres Tennus

Keywords: Adult ADHD, neuropsychiatric genomics, genetic risk variants, machine learning, psychiatric diagnostics, biobank data, European Research Council grant, personalized medicine, neurodevelopmental disorders, mental health biomarkers